Lithium: Still effective despite its detractors

BMJ

Volumn 316, Issue 7141, 1998, Pages 1330-

  Jefferson, James W ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM DERIVATIVE; PSYCHOTROPIC AGENT; LITHIUM;

BIPOLAR DISORDER; EDITORIAL; HUMAN; MENTAL DISEASE; MANIC DEPRESSIVE PSYCHOSIS; PRIORITY JOURNAL;

BIPOLAR DISORDER; HUMANS; LITHIUM COMPOUNDS; MENTAL DISORDERS; PSYCHOTROPIC DRUGS;

EID: 0032474255     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.316.7141.1330     Document Type: Editorial

References (18)

1. Hunter R, Macalpine I. Three hundred years of psychiatry 1535-1860. Hartsdale NY: Carlisle Publishing, 1982:668. Philadelphia, Kimber and Richardson, 1812).
2. Cade JF. The story of lithium. In: Ayd FJ,Blackwell B, eds. Discoveries in biological psychiatry. Philadelphia: Lippincott, 1970: 218-218.
3. Corcoran AC, Taylor RD, Page IH. Lithium poisoning from the use of salt substitutes. JAMA 1949; 139: 685-688.
4. Blackwell B, Shepherd M. Prophylactic lithium: another therapeutic myth? Lancet 1968; 1: 968-971.
5. Moncrieff J. Lithium: evidence reconsidered. Br J Psychiatry 1997; 171: 113-119.
6. Moncrieff J. Lithium revisited: A re-examination of the placebo-controlled trials of lithium prophylaxis in manic-depressive disorder. Br J Psychiatry 1995; 167: 569-574.
7. Cookson J. Lithium: balancing risks and benefits. Br J Psychiatry 1997; 171: 120-124.
8. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 1994; 151(suppl): 1-1.
9. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994; 271: 918-924.
10. Baldessarini RJ, Tondo L, Floris G, Rudas N. Reduced morbidity after gradual discontinuation of lithium treatment for bipolar I and II disorders: A replication study. Am J Psychiatry 1997; 154: 551-553.
11. Goodwin FK, Jamison KR. Manic-Depressive Illness, New York: Oxford University Press, 1990: 665-665.
12. Davis JM, Wang Z, Janicak PG. A quantitative analysis of clinical drug trials for the treatment of affective disorders. Psychopharmacol Bull 1993; 29: 175-181.
13. Wolf T, Müller-Oerlinghausen B, Ahrens B, Grof P, Schou M, Felber W, et al. How to interpret findings on mortality of long-term lithium treated manic-depressive patients? Critique of different methodological approaches. J Affect Dis 1996; 39: 127-132.
14. Baumann P, Souche A, Montaldi S, Baettig D, Lambert S, Uehlinger C, et al. A double blind, placebo controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: A clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996; 16: 307-314.
15. Katona CLE. Refractory depression: A review with particular reference to the use of lithium augmentation. Eur Neuropsychopharmacol 1995; 5(suppl): 109-109.
16. Bernadt M, Stein G. Lithium: evidence reconsidered. Br J Psychiatry 1997; 171: 484.
17. Gitlin MJ, Altshuler LL. Unanswered questions, unknown future for one of our oldest medications. Arch Gen Psychiatry 1997; 54: 21-23.
18. In: Strauss MB, ed. Familiar medical quotations, Boston: Little, Brown, 1968: 493.